BioLineRx Ltd. (BLRX)

BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of $39.47 million. The enterprise value is $30.60 million.

Market Cap	39.47M
Enterprise Value	30.60M

Important Dates

The next estimated earnings date is Monday, November 18, 2024, before market open.

Earnings Date	Nov 18, 2024
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 1.20 billion shares outstanding. The number of shares has increased by 22.24% in one year.

Current Share Class	n/a
Shares Outstanding	1.20B
Shares Change (YoY)	+22.24%
Shares Change (QoQ)	+10.21%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.09B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1.80
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.61, with a Debt / Equity ratio of 2.24.

Current Ratio	1.61
Quick Ratio	1.44
Debt / Equity	2.24
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-12.03

Financial Efficiency

Return on equity (ROE) is -171.94% and return on invested capital (ROIC) is -54.52%.

Return on Equity (ROE)	-171.94%
Return on Assets (ROA)	-35.23%
Return on Capital (ROIC)	-54.52%
Revenue Per Employee	$215,797
Profits Per Employee	-$381,253
Employee Count	79
Asset Turnover	0.28
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -71.86% in the last 52 weeks. The beta is 0.80, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	-71.86%
50-Day Moving Average	0.53
200-Day Moving Average	0.76
Relative Strength Index (RSI)	42.68
Average Volume (20 Days)	384,830

Short Selling Information

Short Interest	621,386
Short Previous Month	137,659
Short % of Shares Out	0.78%
Short % of Float	n/a
Short Ratio (days to cover)	1.94

Income Statement

In the last 12 months, BioLineRx had revenue of $17.05 million and -$30.12 million in losses. Loss per share was -$0.03.

Revenue	17.05M
Gross Profit	11.00M
Operating Income	-34.82M
Pretax Income	-49.15M
Net Income	-30.12M
EBITDA	-33.08M
EBIT	-34.82M
Loss Per Share	-$0.03

Balance Sheet

The company has $40.06 million in cash and $31.26 million in debt, giving a net cash position of $8.81 million or $0.01 per share.

Cash & Cash Equivalents	40.06M
Total Debt	31.26M
Net Cash	8.81M
Net Cash Per Share	$0.01
Equity (Book Value)	13.98M
Book Value Per Share	0.01
Working Capital	18.59M

Cash Flow

In the last 12 months, operating cash flow was -$30.35 million and capital expenditures -$76,000, giving a free cash flow of -$30.42 million.

Operating Cash Flow	-30.35M
Capital Expenditures	-76,000
Free Cash Flow	-30.42M
FCF Per Share	-$0.03

Margins

Gross margin is 64.55%, with operating and profit margins of -204.22% and -176.67%.

Gross Margin	64.55%
Operating Margin	-204.22%
Pretax Margin	-176.67%
Profit Margin	-176.67%
EBITDA Margin	-194.04%
EBIT Margin	-204.22%
FCF Margin	-247.25%

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.24%
Shareholder Yield	-22.24%
Earnings Yield	-76.31%
FCF Yield	-77.08%

Analyst Forecast

The average price target for BioLineRx is $11.50, which is 2,559.57% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.50
Price Target Difference	2,559.57%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on July 15, 2019. It was a reverse split with a ratio of 0.0666666:1.

Last Split Date	Jul 15, 2019
Split Type	Reverse
Split Ratio	0.0666666:1

Scores

BioLineRx has an Altman Z-Score of -8.56. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.56
Piotroski F-Score	n/a